Education
About Us
Working with TipRanks
Follow Us
XHE - ETF AI Analysis
Top Page
SPDR S&P Health Care Equipment ETF (XHE)
Rating:64Neutral
Price Target:
$85.00
Positive Factors
Focused Sector Exposure
The ETF is heavily concentrated in the health care equipment sector, which can benefit from long-term demand for medical innovation.
Reasonable Expense Ratio
The fund charges a relatively low expense ratio, making it cost-effective compared to many actively managed funds.
Steady Recent Performance
The ETF has shown positive returns over the last three months, indicating some recovery in its holdings.
Negative Factors
Weak Year-to-Date Performance
The ETF has struggled overall this year, with negative year-to-date returns reflecting challenges in the sector.
Underperforming Top Holdings
Several of the largest positions, such as Tandem Diabetes Care and NovoCure, have seen significant declines this year, dragging down the fund.
Geographic Over-Concentration
The ETF is almost entirely invested in U.S. companies, limiting exposure to international markets and diversification.
XHE vs. SPDR S&P 500 ETF (SPY)
AUM135.68M
RegionNorth America
Expense Ratio0.35%
Beta0.89
IssuerState Street
Inception DateJan 26, 2011
Dividend Yield0.07%
Asset ClassEquity
Index TrackedS&P Healthcare Equipment Select Industry
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume31,038
30 Day Avg. Volume20,204
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
102.49Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering66
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XHE Summary
The SPDR S&P Health Care Equipment ETF (XHE) is an investment fund that focuses on companies in the health care equipment and supplies industry. It follows the S&P Health Care Equipment Select Industry Index, which includes businesses leading medical innovation. Some well-known companies in this ETF are Medtronic and Hologic, both of which manufacture advanced medical devices. Investors might consider XHE for its potential growth, as health care equipment is essential and constantly evolving. However, new investors should note that this ETF is heavily concentrated in the health care sector, meaning its performance could be impacted by changes in health care regulations or industry trends.
How much will it cost me?The SPDR S&P Health Care Equipment ETF (XHE) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which often requires more active management compared to broad-market index funds. However, it provides targeted exposure to the innovative health care equipment industry.
What would affect this ETF?The SPDR S&P Health Care Equipment ETF (XHE) could benefit from increased demand for innovative medical technologies and devices, driven by aging populations and advancements in health care. However, it may face challenges from regulatory changes, rising interest rates that impact growth-focused companies, or economic slowdowns that reduce health care spending. Its U.S.-focused portfolio and reliance on the health care equipment sector make it sensitive to domestic policy shifts and sector-specific trends.
XHE Top 10 Holdings
The SPDR S&P Health Care Equipment ETF (XHE) is heavily concentrated in the U.S. health care equipment sector, with a mix of rising and lagging performers shaping its trajectory. TransMedics Group stands out as a bright spot, benefiting from robust growth and strategic initiatives, while Medtronic has shown steady performance, supported by strong financials and stable technical indicators. On the flip side, NovoCure and Neogen are holding the fund back, grappling with financial challenges and valuation concerns. Overall, the fund’s focus on innovative medical technology offers long-term potential, but near-term performance remains mixed.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| AxoGen | 2.43% | $3.32M | $1.10B | 58.89% | 61 Neutral | |
| Alphatec Holdings | 2.26% | $3.08M | $2.88B | 126.34% | 58 Neutral | |
| Intuitive Surgical | 2.17% | $2.97M | $191.01B | 4.59% | 78 Outperform | |
| TransMedics Group | 2.09% | $2.85M | $4.18B | 47.24% | 78 Outperform | |
| Tandem Diabetes Care | 2.09% | $2.85M | $1.03B | -54.06% | 46 Neutral | |
| Idexx Laboratories | 2.04% | $2.79M | $57.66B | 73.59% | 78 Outperform | |
| Hologic | 2.04% | $2.79M | $16.49B | -5.95% | 69 Neutral | |
| Neogen | 2.03% | $2.77M | $1.31B | -59.79% | 51 Neutral | |
| Lantheus | 1.94% | $2.66M | $3.92B | -49.80% | 69 Neutral | |
| Edwards Lifesciences | 1.91% | $2.60M | $49.40B | 26.18% | 76 Outperform |
XHE Technical Analysis
Positive
―
Price Trends
80.34
Positive
79.97
Positive
82.09
Negative
Market Momentum
0.23
Negative
54.73
Neutral
42.35
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XHE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 80.14, equal to the 50-day MA of 80.34, and equal to the 200-day MA of 82.09, indicating a neutral trend. The MACD of 0.23 indicates Negative momentum. The RSI at 54.73 is Neutral, neither overbought nor oversold. The STOCH value of 42.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XHE.
XHE Peer Comparison
Comparison Results
Performance Comparison
XHE
SPDR S&P Health Care Equipment ETF
81.06
-12.64
-13.49%
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
PJP
Invesco Dynamic Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents